CT-Guided Transthoracic Needle Biopsy for Evaluation of PD-L1 Expression: Comparison of 22C3 and SP263 Assays

被引：1
|
作者：
Beck, K. [1 ]
Lee, K. Y. [2 ]
Hong, S. J. [3 ]
机构：
[1] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Radiol, Seoul, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Pathol, Seoul, South Korea
[3] Hanyang Univ, Guri Hosp, Coll Med, Radiol, Guri, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
CT-guided biopsy; PD-L1; assay;
D O I：
10.1016/j.jtho.2018.08.421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA13.01
引用
收藏
页码：S399 / S400
页数：2
相关论文
共 50 条
  • [1] CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays
    Beck, Kyongmin S.
    Kim, Seung Joon
    Kang, Jin Hyoung
    Han, Dae Hee
    Jung, Jung Im
    Lee, Kyo Young
    THORACIC CANCER, 2019, 10 (07) : 1612 - 1618
  • [2] Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC
    Sughayer, Maher A.
    Alnaimy, Farah
    Alsughayer, Anas M.
    Qamhia, Naim
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (09) : 663 - 666
  • [3] PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays
    Dabbagh, Tamara Z.
    Sughayer, Maher A.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (06) : 462 - 466
  • [4] External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different
    Dodson, Andrew
    Parry, Suzanne
    Lissenberg-Witte, Birgit
    Haragan, Alex
    Allen, David
    O'Grady, Anthony
    McClean, Emma
    Hughes, Jamie
    Miller, Keith
    Thunnissen, Erik
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2020, 6 (02): : 138 - 145
  • [5] Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263
    Fujimoto, Daichi
    Yamashita, Daisuke
    Fukuoka, Junya
    Kitamura, Yuka
    Hosoya, Kazutaka
    Kawachi, Hayato
    Sato, Yuki
    Nagata, Kazuma
    Nakagawa, Atsushi
    Tachikawa, Ryo
    Date, Naoki
    Sakanoue, Ichiro
    Hamakawa, Hiroshi
    Takahashi, Yutaka
    Tomii, Keisuke
    ANTICANCER RESEARCH, 2018, 38 (12) : 6891 - 6895
  • [6] Pitfalls of PD-L1 Immunohistochemistry: A Comparison of 22C3 and SP263 antibodies Across Laboratories and Pathologists
    Wilberger, Adam
    Aisner, Dara
    Merrick, Daniel T.
    MODERN PATHOLOGY, 2018, 31 : 756 - 757
  • [7] Pitfalls of PD-L1 Immunohistochemistry: A Comparison of 22C3 and SP263 antibodies Across Laboratories and Pathologists
    Wilberger, Adam
    Aisner, Dara
    Merrick, Daniel T.
    LABORATORY INVESTIGATION, 2018, 98 : 756 - 757
  • [8] Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors
    Marchetti, Antonio
    Barberis, Massimo
    Franco, Renato
    De Luca, Graziano
    Pace, Maria Vittoria
    Staibano, Stefania
    Volante, Marco
    Buttitta, Fiamma
    Guerini-Rocco, Elena
    Righi, Luisella
    D'antuono, Tommaso
    Scagliotti, Giorgio V.
    Pinto, Carmine
    De Rosa, Gaetano
    Papotti, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : 1654 - 1663
  • [9] PD-L1 status in Taiwanese lung adenocarcinoma patients: Comparison of PD-L1 immunohistochemical assays using antibody clones 22C3, SP142 and SP263 with clinicopathological correlation
    Yeh, Y-C.
    Lin, S-F.
    Chiu, C-H.
    Wu, Y-C.
    Hsieh, W-Y.
    Ho, H-L.
    Chou, T-Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study
    Paliogiannis, Panagiotis
    Lobrano, Renato
    Bella, Michele Angelo
    Fara, Antonella
    Uras, Maria Gabriela
    Pinna, Maria Antonia
    Tedde, Alessandro
    Madonia, Massimo
    Zinellu, Angelo
    Cossu, Antonio
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 69
12345